TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00786370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Propofol or dexmedetomidine infusion will be started according to the randomized treatment allocation. The propofol group will receive a bolus of 2mg midazolam and 100mcg fentanyl and then continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved. The dexmedetomidine group will receive a bolus of dexmedetomidine 1mcg/kg for 10 minutes and then a continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexemedetomidine
Description: continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
Study: NCT02141828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPZ-5676
Description: 28-day continuous IV infusion of each 28-day cycle, given until disease progression or unacceptable toxicity develops.
Study: NCT04986319

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum vitamin D assay
Description: Trained phlebotomists will collect 10 cc of a Blood sample. Specimen will be preserved at -40ºc for batch analysis.~S Vitamin D, S iPTH, S Calcium, S Alkaline Phosphatase, S PO4, S Mg, S Albumin and S Creatinine will be done in BIRDEM laboratory. Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: The ARCHITECT 25-OH Vitamin D assay is a chemiluminescent micro-particle immunoassay (CMIA). This technology is used for the quantitative analysis of 25(OH) D and aid in the assessment of vitamin D sufficiency.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum vitamin D assay
Description: Trained phlebotomists will collect 10 cc of a Blood sample. Specimen will be preserved at -40ºc for batch analysis.~S Vitamin D, S iPTH, S Calcium, S Alkaline Phosphatase, S PO4, S Mg, S Albumin and S Creatinine will be done in BIRDEM laboratory. Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: The ARCHITECT 25-OH Vitamin D assay is a chemiluminescent micro-particle immunoassay (CMIA). This technology is used for the quantitative analysis of 25(OH) D and aid in the assessment of vitamin D sufficiency.
Study: NCT03765034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constrain-induced Movement Therapy
Description: 8-week therapy program utilizing constraint of the unaffected arm

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Occupational Therapy
Description: 8-week therapy program without constraint of the unaffected arm

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Occupational Therapy
Description: 8-week therapy program without constraint of the unaffected arm
Study: NCT04000854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide (Calacept)
Description: Long-term follow up of pulp regenerative treatment using two different root canal dressings: calcium hydroxide and chlorhexidin digluconate in immature necrotic traumatized incisiors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide (Calacept)
Description: Long-term follow up of pulp regenerative treatment using two different root canal dressings: calcium hydroxide and chlorhexidin digluconate in immature necrotic traumatized incisiors
Study: NCT04562818

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: Determine the number of center that are able to process PCR or FISH/Karyotype for PML/RAR or t(15;17)

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: Determine the number of center that are able to process PCR or FISH/Karyotype for PML/RAR or t(15;17)

Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular and Karyotype
Description: To realize the need of having more center we the technology to perform all of these tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular and Karyotype
Description: To realize the need of having more center we the technology to perform all of these tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Leucocytes

Intervention type: DIAGNOSTIC_TEST
Intervention: Leucocytes
Study: NCT00958906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab (intravitreal, 2.0mg/0.05ml)
Description: One injection of intravitreal infliximab (2.0mg/0.05ml).
Study: NCT03101332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality cognitive behavior therapy
Description: Cognitive interventions targeted to change catastrophic misinterpretations of the physiological symptoms that occur during a panic attack.~Exposure via Virtual Reality to filmed sequences of environments typically feared by agoraphobic patients such as underground station/train, a tunnel, a lift and a public square, as well as exposure to the feared symptoms that occur in a typical panic attack.~Interventions are delivered by a psychologist in face-to-face sessions.
Study: NCT01506804

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: Steroid injection X 2 and 10 weeks exercise program of painful shoulder vs exercise program of contralateral shoulder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Steroid injection X 2 and 10 weeks exercise program of painful shoulder vs exercise program of contralateral shoulder
Study: NCT00409552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality based distraction
Description: Participants will undergo virtual reality based distraction using the head display while they go through the pain process.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR with flat projection display
Description: VR with flat projection display

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: non-interactive video with head display
Description: non-interactive video with head display

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: non-interactive video with with flat projection display
Description: non-interactive video with with flat projection display
Study: NCT04323657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-110 T Cells
Description: TC-110 T Cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-110 T Cells
Description: TC-110 T Cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Flu/Cy Lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Flu/Cy Lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Flu/Cy Lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Flu/Cy Lymphodepletion
Study: NCT01136083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Subjects in exercise group will undergo individualized high aerobic interval training on treadmill for 30 minutes under the supervision of an experienced physical therapist 3 times a week and home exercise twice a week with accelerometer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Subjects in control group will not undergo individualized high aerobic interval training on treadmill. They will receive usual care as normally does in hospital.
Study: NCT00517088

Intervention type: DRUG
Group type: OTHER
Intervention: IPAQ
Study: NCT00659737

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aprepitant
Description: 40mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine
Description: 1.5 mg patch delivering transdermally in vivo approx. 1.0mg over 3 days
Study: NCT00351052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecroliums cream 1 % bid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle control (placebo) bid.
Study: NCT02510677

Intervention type: OTHER
Group type: OTHER
Intervention: myocardial perfusion scintigraphy
Study: NCT02037308

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bread
Study: NCT01823913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test formulation
Description: A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference formulation
Description: A single oral dose of a combination tablet of amlodipine besylate 10mg and valsartan 160mg
Study: NCT01897818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: communication system P300 Speller
Study: NCT01157403

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous transplantation
Description: Autologous transplantation of bone marrow mesenchymal stem cells (approximately 2.5 x 106 cells/kg body weight) intravenously
Study: NCT01956916

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Description: Capsules containing lyophilized 6x10\^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months
Study: NCT00853632

Intervention type: DEVICE
Group type: OTHER
Intervention: CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES
Description: Mitral valve replacement
Study: NCT01908803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-60371/AL-817 otic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension
Description: CIPRODEX®
Study: NCT03677453

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Perioperative Teaching Platform
Description: An active video format will be used to provide instructions for navigating the hospital; describe induction of anesthesia and the surgical procedure; and provide post-surgery and post-discharge instructions for pain management.
Study: NCT00742235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ergocalciferol
Description: Ergocalciferol 50,000 IU given every other day for 5 total doses
Study: NCT00485134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 240 µg Shigella flexneri 2a Invaplex 50 vaccine
Description: Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 240 µg Shigella flexneri 2a Invaplex 50 vaccine
Description: Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 480 µg Shigella flexneri 2a Invaplex 50 vaccine
Description: Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 690 Shigella flexneri 2a Invaplex 50 vaccine
Description: Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Shigella challenge strain
Description: 300 colony forming units (CFU) of Shigella challenge strain, Shigella flexneri 2a strain 2457T

Intervention type: OTHER
Group type: OTHER
Intervention: Shigella challenge strain
Description: 300 colony forming units (CFU) of Shigella challenge strain, Shigella flexneri 2a strain 2457T
Study: NCT00126334

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Packed Red Blood Cell Transfusion
Description: transfusion of 1 unit of PRBCs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Packed Red Blood Cell Transfusion
Description: transfusion of 1 unit of PRBCs
Study: NCT02192281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Playworks
Description: The Playworks program places full-time coaches in low-income schools to provide opportunities for organized play during recess and throughout the school day.
Study: NCT02586649

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium Bromide
Description: Tiotropium bromide is an anticholinergic used to study bronchodilatation and improvement of pulmonary function in tetraplegic patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide
Description: Tiotropium bromide is an anticholinergic used to study bronchodilatation and improvement of pulmonary function in tetraplegic patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a non-active inhalation capsule .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a non-active inhalation capsule .
Study: NCT01684865

Intervention type: DRUG
Intervention: Rituximab
Description: Due to observational nature of the study protocol does not specify any dosing schedule for rituximab.
Study: NCT03257319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled titration of morphine chlorhydrate
Description: Patient in arm A will receive 1 to 3 titration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV placebo
Description: Patient in arm A will receive 1 to 6 injection

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo
Description: Patient in arm B will receive 1 to 3 titration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV titration of morphine chlorhydrate
Description: Patient in arm BA will receive 1 to 6 injection
Study: NCT03735446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Checkpoint kinase 1 (CHK1) inhibitor
Study: NCT01615913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg terbinafine and 2 mg ketoconazole containing patch
Description: A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 3% terbinafine (contains 3-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 3.99 mcg for terbinafine and 1.70 mcg for ketoconazole, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mg terbinafine and 2 mg ketoconazole containing patch
Description: A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 6% terbinafine (contains 6-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 8.52 mcg for terbinafine and 2.03 mcg for ketoconazole, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 mg terbinafine and 2 mg ketoconazole containing patch
Description: A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 8% terbinafine (contains 8-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 10.7 mcg for terbinafine and 2.17 mcg for ketoconazole, respectively.
Study: NCT02467686

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WHOQOL questionnaire
Description: WHO defines Quality of Life as individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: WHOQOL questionnaire
Description: WHO defines Quality of Life as individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FSFI questionnaire
Description: FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: FSFI questionnaire
Description: FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: kupperman scale
Description: Kupperman scale is a tool to help evaluate the severity of menopausal symptoms

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: kupperman scale
Description: Kupperman scale is a tool to help evaluate the severity of menopausal symptoms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimicifuga racemosa
Description: The Cimicifuga racemosa effects on the sexuality of women with Breast cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen
Description: The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tamoxifen
Description: The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using aromatase inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: exemestane
Description: The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using aromatase inhibitor.
Study: NCT02518295

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive control
Description: 200ml milk containing 18g lactose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic S. thermophilus
Description: 200ml milk containing 18g lactose + probiotic S. thermophilus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic B. longum
Description: 200ml milk containing 18g lactose + probiotic B. longum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Negative control
Description: 200 ml of UHT Lactose free milk
Study: NCT04494997

Intervention type: OTHER
Intervention: Survey Questionnaire
Description: This Cross sectional study uses Questionnaire with Closed ended questions. The survey form is designed using Google forms program. Survey initial question seeks CONSENT from the respondent. Survey collects data under 4 sections.~Section I: Demographic details Section II: 6 Questions regarding use of your Social Media for Professional activities.~Section III: 7 Questions regarding the advantages of your Social Media use. Section IV: 5 Questions regarding the disadvantages of your Social Media use.~The Google form questionnaire survey link will be shared with the Dentists in internet via Social Media \&/Or email to seek responses. The link will be available for single response for a single respondent.
Study: NCT01716052

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Lactulose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study: NCT03404752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-Filgrastim
Study: NCT01742117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: One 75 mg tablet per day by mouth for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: One 75 mg tablet per day by mouth for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: One 90 mg tablet twice per day by mouth for one year
Study: NCT02223845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Self-selected music played via headphones
Study: NCT04521504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinematic biofeedback with ISEO motion analysis system
Description: Exercises are performed with the help of the ISEO motion analysis system, that provides a real-time biofeedback of shoulder kinematics. All exercises are administered by the Physical Therapist.
Study: NCT02670239

Intervention type: PROCEDURE
Intervention: normothermic ex vivo lung perfusion
Study: NCT02453347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CES Therapy
Description: Cranial Electrotherapy Stimulation (CES) may serve as an effective complimentary, noninvasive/non-pharmacological treatment for this Veteran population. CES is administered through a therapeutic device (such as Alpha-Stim®) marketed and approved by the FDA to treat insomnia, depression, anxiety, and pain.
Study: NCT02937324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CloudUPDRS smartphone software assessment
Description: Smartphone software consisting of a series of tapping and tremor-measurement tests designed to measure a subset of the UPDRS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical assessment
Description: A clinician will assess the motor signs of the participant using the Unified Parkinson's Disease Rating Scale. The examination will be videoed and rated by 3 blinded examiners.
Study: NCT01994824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit antithymocyte globulin
Description: Thymoglobulin, 3 mg/kg, will be given on day 8 posttransplant to patients at high risk of significant GVHD per day 7 IL15 and IL2Ra levels.
Study: NCT02285608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PIMM/SAM
Description: The PIMM program will include education to improve patients' knowledge regarding their medication's purpose, dosage, benefits, and side effects. The program will also include tools like a checklist or alarm clock to remind patients of when and how to take their medication. Furthermore, the program will contain an interactive listening period where healthcare professionals involved in medication dispensing will listen to patients' concerns, questions and thoughts regarding their medications.